Have a personal or library account? Click to login
Parameters of dynamic spirometry before and after administration of salbutamol in COPD patients Cover

Parameters of dynamic spirometry before and after administration of salbutamol in COPD patients

Open Access
|Oct 2024

References

  1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2021 report [internet], Global Initiative for Chronic Obstructive Lung Disease; 2021 [cited 2021 Aug 8]. Available from: https://goldcopd.org/
  2. Buist AS, McBurnie MA, Vollmer WM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;1;370(9589):741–50. 10.1016/S0140-6736(07)61377-4 [PubMed] [CrossRef] [Google Scholar]
  3. Chronic obstructive pulmonary disease (COPD) in Vietnam [internet]. Geneva: World Health Organization; 2021. [cited 2021 Oct 20]. Available from: https://www.who.int/vietnam/health-topics/chronic-obstructive-pulmonary-disease-copd
  4. Chronic obstructive pulmonary disease (COPD). Geneva: World Health Organization; 2021. [cited 2021 Oct 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
  5. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the noncommunicable disease crisis. Lancet. 2011;377:1438–1447
  6. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet. 2021;397:928–940.
  7. Asher MI, Rutter CE, Bissell K, et al. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study. Lancet. 2021;398:1569–1580.
  8. Halpin DMG, Celli BR, Criner GJ, et al. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. Int J Tuberc Lung Dis. 2019;23:1131–1141.
  9. WHO . World Health Organization; Geneva: 2013. [cited 2023 Oct 24] Global Action Plan for the prevention and control of noncommunicable diseases 2013–2020.
  10. Global Initiative for Chronic Obstructive Lung Disease. 2023. [cited 2023 Oct 24] Available from: https://goldcopd.org/2023-gold-report-2/
  11. Alsuwaigh R, Yii A, Loh CH, Xu X, Bahety P, Navarro Rojas AA, Milea D, Tee A. A comparison of GOLD 2019 and 2023 recommendations to contemporaneous real-world inhaler treatment patterns for chronic obstructive pulmonary disease management in Singapore. J Thorac Dis. 2024;16(2):847-861. doi: 10.21037/jtd-22-1769. Epub 2024 Feb 21. PMID: 38505044; PMCID: PMC10944796.
  12. Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022;206:1317–1325.
  13. Global Initiative for Chronic Obstructive Lung Disease. 2022. [cited 2023 Oct 24]Available from: www.goldcopd.org
  14. Agustí A, Melén E, DeMeo DL, Breyer-Kohansal R, Faner R. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. Lancet Respir Med. 2022;10:512–524.
  15. Vollmer WM, Gíslason T, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009; 343:588-597.
  16. Agusti A, Vogelmeier CF. GOLD 2024: a brief overview of key changes. J Bras Pneumol. 2023;49(6):e20230369. doi: 10.36416/1806-3756/ e20230369. PMID: 38126685; PMCID: PMC10760434
  17. Cazzola M. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal. 2008;31.2: 416-469.
  18. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;1154:957-965.
  19. Schermer T, Heijdra Y, Zadel S, et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med. 2007;101(6):1355-62.
  20. Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. The Lancet Respiratory Medicine 2013;1(7): 564-573.
  21. Svensson L,  Ankerst J,  Bjermer L,  Tufvesson E. Airway resistance and reactance in COPD patients and healthy smokers and effect of bronchodilators. European Respiratory Journal. 2011;38(55) : 4053.
  22. Kanda S, Fujimoto K, Komatsu Y, Yasuo M, Hanaoka M, Kubo K. Evaluation of respiratory impedance in asthma and COPD by an impulse oscillation system. Intern Med. 2010;49(1):23-30.
DOI: https://doi.org/10.2478/amma-2024-0019 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 122 - 134
Submitted on: Apr 30, 2024
Accepted on: Jun 27, 2024
Published on: Oct 2, 2024
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Medžida Rustempašić, Muamer Dervišević, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.